Valeant Estimates Peak Sales Of $1.5 Billion For Epilepsy Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Company reports positive data from second Phase III trial of retigabine, a first-in-class neuronal potassium channel opener.
You may also be interested in...
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
GSK And Valeant Partner On Epilepsy Candidates
$125 million upfront deal could ameliorate impact of 2010 Lamictal patent expiry for GSK.
Valeant Will Trim Its Focus To North America, Concentrate On Neurology And Dermatology
Firm also plans to partner lead candidates retigabine and taribavirin, new CEO Pearson says.